Tests desloratadine added to standard treatment for rheumatoid arthritis
Tests desloratadine or placebo added to usual care in adults with active rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: Desloratadine as Adjunct Therapy for Rheumatoid Arthritis
Key facts
- Where
- Al Mansurah, EgyptSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07632872, who can take part
Where in Egypt
- Faculty of Medicine, Mansoura UniversityAl Mansurah, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Horus University
- Trial code
- NCT07632872
- Record updated
- 8 June 2026
- Original description
Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and reduced physical function. Although standard disease-modifying antirheumatic drugs are effective for many patients, some individuals continue to have active disease.Read full original descriptionShow less
Effect of Desloratadine as Add-On Therapy in Rheumatoid Arthritis
Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and reduced physical function. Although standard disease-modifying antirheumatic drugs are effective for many patients, some individuals continue to have active disease.
The purpose of this study is to evaluate the effectiveness and safety of adding desloratadine to standard therapy in patients with active rheumatoid arthritis. Participants will receive either desloratadine or placebo in addition to their usual treatment.
The study will assess changes in disease activity and inflammatory markers over a follow-up period of approximately 12 weeks. The results of this study may help determine whether desloratadine could be a useful add-on treatment option for patients with rheumatoid arthritis.
Inclusion: Patients with active rheumatoid arthritis according to the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria; Disease Activity Score in 28 joints (DAS28) greater than 2.6; Age between 18 and 60 years; Male and female patients; Patients receiving methotrexate in addition to standard conventional therapy; Ability to provide written informed consent.
Exclusion: Current treatment with biological disease modifying antirheumatic drugs; Patients with renal or hepatic disease; Known hypersensitivity to the study medications; History of psychiatric disorders; History of cardiac arrhythmias or prolonged QT interval; Use of medications known to prolong the QT interval; Current use of antioxidant supplements; Use of oral prednisolone at a dose greater than 15 mg per day; Pregnant or breastfeeding patients.